Rigel (RIGL) Q4 2025 earnings review
Record Top-Line, Illusionary Bottom-Line, Decelerating Future
Rigel had a blockbuster 2025, but the market looks forward, and the forward view is slowing down. While Q4 product sales jumped 41% YoY to $65.4M, 2026 guidance implies a sharp deceleration to ~12% growth from this year's 60% surge. Furthermore, the massive $268.1M Q4 Net Income print is an illusion—$245.9M of it is a one-time, non-cash tax benefit. Stripping the noise, core operations are genuinely profitable (Operating Income hit $23.2M), but the hyper-growth phase driven by GAVRETO integration and IRA tailwinds is clearly stabilizing.
🐂 Bull Case
Stripping away the massive tax benefit, Rigel generated $23.2M in Q4 Operating Income. The company has successfully transitioned into a self-sustaining commercial biotech, ending the year with a robust $155M cash balance to fund internal pipeline advancement.
The anchor asset continues to deliver. TAVALISSE generated $45.6M in Q4 (up 47% YoY), proving that the demand acceleration seen earlier in the year was not a fluke, but a sustained expansion of the patient base.
🐻 Bear Case
2025 was a 60% growth year for product sales. 2026 guidance of $255-$265M implies just ~12% growth. The easy comps from the GAVRETO acquisition and initial Inflation Reduction Act (IRA) tailwinds are officially over.
Research & Development costs nearly doubled YoY in Q4 to $10.7M. As R289 and olutasidenib advance into deeper, more expensive trials, maintaining strong operating margins will become increasingly difficult.
⚖️ Verdict: ⚪
Neutral. Rigel executed a flawless 2025, validating its commercial portfolio and solidifying the balance sheet. However, the 2026 guidance indicates the high-growth phase is decelerating, and the headline Net Income number drastically overstates actual cash generation.
Key Themes
The GAAP Net Income Illusion
Investors must look past the headline. Rigel reported an eye-popping $268.1M in Q4 Net Income, but $245.9M of this was a non-cash deferred income tax benefit. True Q4 Operating Income was $23.2M. While still a massive improvement from $16.7M a year ago, the headline earnings per share ($13.54 diluted) is disconnected from the cash reality.
Commercial Execution Stabilizing at Higher Plateau
Rigel's three-headed commercial strategy is working. TAVALISSE ($45.6M, +47%), GAVRETO ($10.2M, +27%), and REZLIDHIA ($9.6M, +29%) all grew in Q4. However, sequential growth is flattening. GAVRETO actually dipped from $11.1M in Q3 to $10.2M in Q4, signaling that the initial integration surge is complete.
Balance Sheet War Chest Assembled
Rigel ends 2025 in a radically different financial position than it started. Cash and short-term investments doubled from $77.3M at the end of 2024 to $155.0M. Management now has the self-funded capability to aggressively pursue late-stage M&A and in-licensing without diluting shareholders.
R&D Expense Inflation Resumes
After a period of tight cost control, R&D expenses are accelerating, jumping 90% YoY in Q4 to $10.7M. This is driven directly by clinical momentum: advancing R289 into dose expansion and initiating new olutasidenib trials. While necessary for pipeline value, it will act as a headwind to 2026 margins.
R289 Program Advancing Toward Value Inflection
The Phase 1b study for R289 (IRAK1/4 inhibitor) in lower-risk MDS successfully enrolled its first patient in the dose expansion phase. With a 33% transfusion independence rate shown at doses >= 500mg QD, Rigel is on track to select a Phase 2 dose in H2 2026. This asset is the primary catalyst for the company's internal pipeline valuation.
Other KPIs
Accelerating. Up 39% from $16.7M in 24Q4. This is the cleanest metric to evaluate Rigel's quarter, stripping away the massive Q4 tax benefit and avoiding the non-cash revenue bumps (like the $40M Lilly benefit) that inflated prior quarters.
Inflated by one-time items. Up from $34.4M in 2024, but this includes the $40.0M non-cash release of the Lilly liability from Q2. Stripping that out, base collaboration revenue is roughly $22.3M, which aligns cleanly with 2026 guidance.
Accelerating. Up 14% from $40.9M in 24Q4. The primary culprit was the $5M spike in R&D, while SG&A remained remarkably flat ($30.0M vs $29.5M), demonstrating strong operating leverage on the commercial side.
Guidance
Reversing. Down slightly from $294.3M in FY25. However, FY25 included $40M in one-time, non-cash contract revenue. On an underlying basis, this represents modest growth.
Decelerating. The midpoint of $260M implies roughly 12% YoY growth compared to the $232M achieved in 2025. This is a dramatic slowdown from the 60% growth rate achieved in 2025, signaling the end of the IRA-boosted hyper-growth phase.
Stable. Down significantly from $62.3M in FY25, but strictly due to the absence of the $40M one-time Lilly accounting benefit. This range represents a normalized expectation for ongoing royalties and drug supply deliveries from partners like Grifols and Kissei.
Stable. The company expects to remain profitable while fully funding its expanded clinical trials. However, investors should expect drastically lower GAAP net income than 2025, which was heavily skewed by the Q4 deferred tax benefit.
Key Questions
Decelerating 2026 Top-Line Expectations
Net product sales guidance implies a sharp deceleration to ~12% growth. What specific headwinds are factored into this model? Are you assuming IRA-driven demand tailwinds have fully normalized, or is there anticipated pressure on GAVRETO or REZLIDHIA?
Capital Allocation with $155M Cash
With the balance sheet vastly strengthened and operations self-funding, what is the specific timeframe and criteria for acquiring or in-licensing new late-stage hematology/oncology assets?
Future Tax Rate Modeling
Given the recognition of the $245.9M deferred income tax benefit in Q4, how should analysts model Rigel's effective tax rate and cash taxes paid for 2026 and beyond?